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ORIGINAL ARTICLE
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ABSTRACT
Objective: To investigate the relation between the need for red blood 
cell transfusion and serum levels of soluble-Fas, erythropoietin and 
inflammatory cytokines in critically ill patients with and without acute 
kidney injury. Methods: We studied critically ill patients with acute kidney 
injury (n=30) and without acute kidney injury (n=13), end-stage renal 
disease patients on hemodialysis (n=25) and healthy subjects (n=21). 
Serum levels of soluble-Fas, erythropoietin, interleukin 6, interleukin 10, 
iron status, hemoglobin and hematocrit concentration were analyzed 
in all groups. The association between these variables in critically ill 
patients was investigated. Results: Critically ill patients (acute kidney 
injury and non-acute kidney injury patients) had higher serum levels of 
erythropoietin than the other groups. Hemoglobin concentration was 
lower in the acute kidney injury patients than in other groups. Serum 
soluble-Fas levels were higher in acute kidney injury and end-stage renal 
disease patients. Critically ill patients requiring red blood cell transfusions 
had higher serum levels of soluble-Fas (5,906±2,047 and 1,920±1,060; 
p<0.001), interleukin 6 (518±537 and 255+502; p=0.02) and interleukin 
10 (35.8±30.7 and 18.5±10.9; p=0.02), better iron status and higher 
mortality rates in the first 28 days in intensive care unit. Serum soluble-
Fas levels were independently associated with the number of red 
blood cell units transfused (p=0.02). Serum soluble-Fas behaved as 
an independent predictor of the need for red blood cell transfusion in 
critically ill patients (p=0.01). Conclusions: Serum soluble-Fas level 
is an independent predictor of the need for red blood cell transfusion in 
critically ill patients with or without acute kidney injury. Further studies 
are warranted to reconfirm this finding.
Keywords: Anemia; Inpatients; Erythrocyte transfusion; Critical illness; 
Hemoglobins; Intensive care units
RESUMO
Objetivo: Investigar a relação entre a transfusão de hemácias e os 
níveis séricos de Fas solúvel, eritropoietina e citocinas inflamatórias 
em pacientes gravemente enfermos, com e sem insuficiência renal 
aguda. Métodos: Os seguintes grupos foram estudados: pacientes 
gravemente enfermos com insuficiência renal aguda (n=30) e sem 
insuficiência renal aguda (n=13), pacientes portadores de doença 
renal crônica terminal em hemodiálise (n=25) e indivíduos saudáveis 
(n=21). Os níveis séricos de Fas solúvel, eritropoietina, interleucina 
6, interleucina 10 e ferro, além da concentração de hemoglobina e 
de hematócrito, foram analisados em todos os grupos. A associação 
entre tais variáveis foram estudadas nos pacientes gravemente 
enfermos. Resultados: Os níveis séricos de eritropoietina mostraram-
se mais elevados nos pacientes gravemente enfermos do que nos 
dos demais grupos. Concentrações mais baixas de hemoglobina 
foram documentadas nos pacientes com insuficiência renal aguda 
em relação aos demais. Níveis séricos mais elevados de Fas solúvel 
foram observados nos pacientes com insuficiência renal aguda e 
doença renal crônica terminal. Pacientes gravemente enfermos 
transfundidos apresentaram níveis séricos mais elevados de Fas 
solúvel (5.906±2.047 e 1.920±1.060; p<0,001), interleucina 6 
(518±537 e 255±502; p=0,02), interleucina 10 (35,8±30,7 e 
18,5±10,9; p=0,02) e ferro, além de maior mortalidade em 28 dias. 
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Os níveis séricos de Fas solúvel mostraram-se independentemente 
associados ao número de transfusões (p=0,02). O nível sérico de Fas 
solúvel foi um preditor independente da necessidade de transfusão de 
hemácias em pacientes gravemente enfermos (p=0,01). Conclusão: 
O nível sérico de Fas solúvel é um preditor independente da 
necessidade de transfusão de hemácias em pacientes gravemente 
enfermos, com ou sem insuficiência renal aguda. Mais estudos 
clínicos e laboratoriais são necessários para confirmar tal resultado. 
Descritores: Anemia; Pacientes internados; Transfusão de eritrócitos; 
Estado terminal; Hemoglobinas; Unidades de terapia intensiva
INTRODUCTION
Critically ill patients are at high risk for anemia and 
have high mortality rates(1,2). Red blood cell transfusion 
is often required to treat anemia in these patients(1-3).
Anemia develops early in the course of critical 
illness(2,3) and has several consequences in critically ill 
patients. Therapeutic options and intensive care unit 
(ICU) hospitalization are costly(4).
Red blood cell transfusions improve oxygen delivery 
in critically ill patients, but not oxygen consumption(4,5). 
The anemia of critical illness is a distinct clinical entity 
with characteristics similar to that of chronic disease 
anemia(4-6). Acute kidney injury (AKI), inflammation and 
erythropoietin (Epo) hyporesponsiveness contribute to 
the progression of anemia in critical illness(5,6). 
Epo is an essential growth factor for erythropoiesis 
and is produced by renal peritubular cells primarily in 
response to low oxygen tension(7,8). 
Fas (CD95) is a transmembrane glycoprotein in the 
same family as tumor necrosis factor alpha (TNF-α)(9). 
CD95 activation is a major mechanism of extrinsic 
apoptosis in several disease processes, including anemia 
of inflammation(9,10). Soluble Fas (s-Fas), a protein 
produced by CD95 alternative splicing, prevents binding 
of CD95-ligand to CD95 in the membrane of different 
cell types(11), with resulting CD95 inactivation and anti-
apoptotic effects, particularly in leukocytes(9-12). 
Increased serum s-Fas levels were demonstrated 
in chronic kidney disease (CKD) and chronic dialysis 
patients and were associated with inflammatory markers, 
anemia and Epo hyporesponsiveness(13). More recently, 
serum s-Fas levels were shown to be related to anemia 
in AKI patients(14) and may therefore be associated with 
the need for red blood cell transfusion in critically ill 
patients. 
OBJECTIVE
We hypothesized that serum s-Fas levels would predict 
the need for red blood cell transfusion in critically ill 
patients. To test this hypothesis, serum levels of s-Fas, 
Epo, inflammatory cytokines, anemia markers, and the 
need for red blood cell transfusion were determined and 
compared in critically ill patients with and without AKI, 
chronic hemodialysis patients and healthy volunteers. 
Correlations between these variables in critically ill 
patients with and without AKI were also investigated. 
METHODS
Subjects and settings
Forty-three critically ill patients with hemoglobin (Hb) 
concentrations ≤10g/dL and therefore potential candidates 
for red blood cell transfusion were prospectively studied. 
Hb concentration, hematocrit (Ht), iron status and 
serum levels of s-Fas, Epo and inflammatory cytokines 
were measured and compared in critically ill patients 
with AKI (AKI patients; n=30) and without AKI (non-
AKI patients; n=13), patients with end-stage renal 
disease requiring hemodialysis (ESRD patients; n=25) 
and healthy volunteers (healthy subjects; n=21). Variables 
were then compared between AKI patients and the 
three remaining groups to investigate the impact of 
renal impairment on serum levels of s-Fas, Epo and 
inflammatory cytokines.
Critically ill patients (n=43) were treated at the ICU 
of Hospital Israelita Albert Einstein in compliance with 
institutional guidelines. Inclusion criteria were age ≥18 
years and at least 24 hours of ICU admission; exclusion 
criteria were pregnancy, coagulation disorders, folate 
and vitamin B12 deficiency, major comorbidities (chronic 
hepatitis B or C and HIV infection), oncologic diseases 
and primary anemic conditions. Patients receiving 
erythropoiesis-stimulating agents were also excluded.
Data on the need for red blood cell transfusions 
within 28 days of follow-up, and up to discharge from 
ICU or death were collected from all critically ill 
patients. In these patients, red blood cell transfusions 
were indicated when Hb concentration dropped below 
7.0g/dL to maintain Hb levels between 7.0 and 9.0g/dL. 
Patients suffering from septic shock, brain injury or 
acute coronary syndrome were considered at high risk 
of anemia-related adverse effects and were transfused 
whenever Hb concentrations dropped below 9.0g/dL 
(Hb levels, 9.0 to 11.0g/dL). 
ESRD patients on hemodialysis were treated at 
Hospital do Rim e Hipertensão of Universidade Federal de 
São Paulo (UNIFESP). Inclusion criteria were age ≥18 
years and ongoing hemodialysis for at least 3 months; 
exclusion criteria included pregnancy, coagulation 
disorders, hematologic diseases or major comorbidities 
(malignancy, conjunctive tissue disease, chronic hepatitis 
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B or C and HIV infection). ESRD patients were dialyzed 
for 3 to 5 hours 3 times weekly. All ESRD patients were 
under treatment either with subcutaneous recombinant 
human erythropoietin, intravenous iron infusion or oral 
vitamin complexes.
Data on AKI and ESRD respective etiologies were 
collected. Critically ill patients were staged according to 
the Acute Physiology and Chronic Health Evaluation 
scale (APACHE II)(15). Renal function assessment was 
based on serum creatinine levels and urine output. AKI 
was defined and staged according to Kidney Disease 
Improving Global Outcomes (KDIGO) criteria(16,17). The 
24-hour water balance of all critically ill patients was 
calculated upon enrollment. All ESRD patients were 
oligoanuric.
Informed consent was given by all patients or next-of-
kin and all healthy volunteers. The study was approved 
by the Research Ethics Committees of Hospital Israelita 
Albert Einstein and UNIFESP.
Laboratory workup
Blood samples were collected from all subjects upon 
enrollment. ESRD patients were sampled before the 
first hemodialysis session of the week and critically ill 
patients 5.5±4.3 days after ICU admission. Healthy 
volunteers were required to fast for a minimum 
of 8 hours prior to blood sampling. Blood samples 
were placed in ice and centrifuged within 1 hour of 
collection. Serum samples were then stored at -80oC 
until analysis.
Serum levels of s-Fas, interleukin-10 (IL-10) and 6 
(IL-6 − BD Biosciences-Pharmigen®, San Diego, CA, 
USA) and Epo (R&D systems®, Minneapolis, USA) 
were measured using enzyme-linked immunoabsorbent 
assay (ELISA). Serum ferritin levels were measured 
with the immunofluorimetric assay (IFMA; AxSYM, 
Abbott®, North Chicago, IL, USA).
Serum creatinine, urea and iron levels, transferrin 
saturation, Hb concentrations and Ht were determined 
using standard automated laboratory techniques. 
Statistical analysis
Logarithmic conversion was used to compare non-
normally distributed variables (serum levels of 
inflammatory cytokines, s-Fas and Epo, iron status 
parameters, red blood cell units transfused and diuresis). 
Continuous variables were expressed as means±SD 
or percentages. Comparisons between groups were 
performed using analysis of variance (ANOVA) and the 
χ2 tests. The Tukey test was employed to determine which 
groups in the sample differed following identification of 
significant differences among groups (ANOVA). Linear 
regression (Pearson’s coefficient) was used in univariate 
analysis. 
Additional comparisons between both groups of 
critically ill patients (AKI and non-AKI) and between 
critically ill patients who required red blood cell 
transfusion in ICU and those who did not were 
performed using the Student´s t test. 
Red blood cell transfusions were treated as dependent 
variables in binary logistic regression. Serum s-Fas 
level values were divided by 1,000 to obtain equalized 
decimal values. Hosmer-Lemeshow goodness-of-fit test 
and Cox & Snell R2 were employed to assess model fit.
The number of red blood cell units transfused 
was also treated as a dependent variable in multiple 
linear regression analysis. Independent variables were 
included in the model whenever p<0.05 in regression 
analyzes. Hb concentrations are directly related to 
the indication of red blood cell transfusion in ICU 
patients and were therefore excluded from the model. 
Regression analyses were performed in a forward stepwise 
fashion.
Differences were considered significant when 
p<0.05 in two-tailed tests. Statistical calculations were 
performed using software Statistical Package for the 
Social Sciences (SPSS), version 20.0 for Windows (SPSS 
Inc. Chicago, IL).
RESULTS
Critically ill patients were older than patients in 
other groups. The male gender predominated across 
all groups. Sepsis, multifactorial etiology and acute 
tubular necrosis were the most frequent causes of 
AKI. ESRD was mostly due to diabetes mellitus and 
hypertension. The 24-hour water balance was higher 
in AKI patients than non-AKI patients. Serum urea 
and creatinine levels were highest in ESRD patients. 
Serum creatinine levels were higher in AKI patients 
than in healthy subjects. Serum urea levels were higher 
in AKI patients than in healthy subjects and non-
AKI patients. Non-AKI patients had higher urine 
output than AKI patients. Hb concentrations and Ht 
were lowest in AKI patients. White blood cell counts 
were higher in AKI patients than ESRD patients and 
healthy subjects (Table 1).
Transferrin saturation and serum levels of ferritin 
and IL-6 were higher in AKI patients. Serum s-Fas 
levels were higher in AKI and ESRD patients than 
in non-AKI patients and healthy subjects. Non-AKI 
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patients had the lowest serum levels of iron. Critically ill 
patients had higher white blood cell counts and serum 
levels of Epo and IL-10. Mean APACHE II scores did 
not differ between AKI and non-AKI patients. AKI 
patients required more red blood cell transfusions, 
mechanical ventilation and vasoactive therapy, and had 
higher mortality rates than non-AKI patients (Table 1).
Patients requiring red blood cell transfusions had 
lower Hb concentrations and Ht. Critically ill patients 
requiring red blood cell transfusions were younger 
and had higher serum levels of s-Fas (Figure 1), IL-
6, iron and ferritin, higher transferrin saturation and 
higher mortality rates than those that did not require 
transfusion (Table 2).
All AKI patients were in disease stage 3 (KDIGO). 
ESRD patients had been started on hemodialysis 1.4±0.8 
years before enrollment.
RBC: red blood cell.
Figure 1. Comparison os serum s-Fas levels between critically ill patient that 
received and that did not receive red blood cell tranfusion wuthin a 28-day follow-up
Table 1. Demographic data and comparisons of baseline laboratory values documented in all groups studied
Variable AKIn=30
non-AKI
n=13
ESRD
n=25
Healthy
n=21 p value
Age (years) 60±19#* 74±17#* 48±13 47±17 <0.001
Gender (% of males) 70 69 68 59 0.79
Renal disease etiology (%) Sepsis (38)
Multifactorial (35)
ATN (27)
NA Diabetes mellitus (39)
Hypertension (37)
Other (16)
CGN (8)
NA -
24-hour water balance (mL)Y +2090±1426 +1517±1074 NA NA 0.006
Creatinine (mg/dL)Y 1.97±0.84# 1.16±0.63 8.57±2.29#F* 0.96±0.16 <0.001
Urea (mg/dL) 135±34.3*# 52±27F* 166±23.3# 26.6±6.01 <0.001
Diuresis (mL)Y 490±640 1517±1074 NA NA <0.001
Hb (g/dL) 8.6±1.3*# 10.2±1.7F# 11.1±1.7# 14.5±1.1 <0.001
Ht (%) 26±4*# 33±6F# 33±5# 43±3 <0.001
WBC (thou/mL) 11.6±7.4*# 12.0±5.2*# 7.6±2.3 6.4±1.5 0.005
Ferritin (mg/L)Y 1390±710*# 576±717F 405±217 95.6±67.7 <0.001
Fe (mg/dL)Y 73.6±61.8 30.2±28.4F*# 79.2±36.1 93.2±19.4 0.004
Transferrin saturation (%)Y 71±46*# 34±27F 31±12 28±7 <0.001
Epo (mIU/mL)Y 97±117*# 43.3±52.8# 16.8±15.6 6.36±3.71 <0.001
s-Fas (pg/mL)Y 4709±2562# 1923±1207F* 4806±674# 1147±369 <0.001
IL-6 (pg/mL)Y 521±583*# 65.3±69.9F*# 6.61±10.9 4.40±6.38 <0.001
IL-10 (pg/mL)Y 29.0±25.1*# 22.3±23.1*# 15.8±65.7 39.6±114 <0.001
RBC transfusions (%)a 17 (76) 4 (31) NA NA <0.001
RBC units transfusedaY 3.7±3.5 0.2±0.6 NA NA 0.001
Vasoactive therapy, n (%)a 25 (83) 4 (31) NA NA 0.001
Mechanical ventilation, n (%)a 26 (87) 5 (38) NA NA 0.001
Sepsis, n (%) 15 (50) 7 (54) NA NA 0.82
APACHE II 32±7 19±11 NA NA 0.35
Mortality, n (%)a 17 (57) 1 (8) NA NA 0.007
# Different from healthy subjects; * different from ESRD patients; F different from AKI patients; Y following log transformation for statistical analysis; a 28-day follow up. AKI: acute kidney injury; ESRD: end-stage renal disease requiring hemodialysis; 
ATN: acute tubular necrosis; NA: not applicable; CGN: chronic glomerulonephritis; Hb: hemoglobin; Ht: hematocrit; WBC: white blood cells; Fe: serum iron; Epo: erythropoietin; s-Fas: soluble Fas; IL: interleukin; RBC: red blood cell.
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RBC: red blood cell.
Figure 2. Correlation between serum levels of s-Fas and number of packed red 
blood cells tranfused
DISCUSSION
The independent effect of serum s-Fas levels on the 
indication of red blood cell transfusions in critically ill 
Table 2. Comparisons of clinical and laboratory data of critically ill patients that 
required red blood cell transfusion and those that did not (n=43)
Variable RBC transfusion (n=21)
non-RBC transfusion 
(n=22) p value
Age (years) 62±20 66±18 0.55
Gender (% of males) 62 81 0.27
ICU primary admission 
diagnosis (%)
Sepsis (40)
CVD (32)
Other (25)
Liver disease (3)
Sepsis (39)
CVD (28)
Other (28)
Liver disease (5)
0.36
Diuresis (mL)Y 529±654 1,087±1,070 0.49
Creatinine (mg/dL) 1.8±0.7 1.4±0.8 0.29
Hb (g/dL) 7.9±0.9 10.2±1.3 <0.001
Ht (%) 25±3 30±5 <0.001
Transferrin saturation (%)Y 76±53 47±29 0.04
Ferritin (mg/L)Y 1451±755 919±761 0.03
Fe (mg/dL)Y 87±66 38±36 0.007
Epo (mIU/mL)Y 103±128 97±99 0.68
RBC units 3.8±3.1 - NA
s-Fas (pg/mL)Y 5,906±2,047 1,920±1,060 <0.001
IL-6 (pg/mL)Y 518±537 255±502 0.02
IL-10 (pg/mL)Y 35.8±30.7 18.5±10.9 0.02
Mortality (%) 13 (76) 4 (24) 0.02
Y following log transformation for statistical analysis. ICU: intensive care unit; CVD: cardiovascular disease; Hb: hemo-
globin; Ht: hematocrit; Fe: serum iron; Epo: erythropoietin serum levels; NA: not applicable; s-Fas: soluble Fas; IL: 
interleukin; RBC: red blood cell.
Table 3. Results of binary logistic regression analysis using red blood cell 
transfusion during the first 28 days in intensive care unit as the dependent 
variable in critically ill patients (n=43)
Variable WALD test p value OR
95%CI
Lowest-Highest
s-Fas (pg/mL) 6.582 0.01 1.080 1.065-1.606
IL-10 (pg/mL) 1.527 0.22 1.068 0.962-1.186
IL-6 (pg/mL) 1.061 0.30 0.996 0.988-1.004
Ferritin (mg/mL) 0.908 0.34 0.999 0.996-2.698
Transferrin saturation (%) 0.022 0.88 0.635 0.100-1.793
OR: odds ratio; 95%IC: 95% confidence interval; s-Fas: soluble Fas; IL: interleukin. 
Table 4. Results of multiple linear regression using the number of red blood cell 
units transfused as the dependent variable in critically ill patients (n=43)
Variable Correlation p value
s-Fas (pg/mL)Y 0.62 0.02
Ferritin (mg/L)Y 0.20  0.21
IL-6 (pg/L)Y 0.18 0.29
Fe (mg/dL)Y 0.08 0.74
Transferrin saturation (%)Y -0.07 0.76
Y Following log transformation for statistical analysis. s-Fas: soluble Fas; IL: interleukin; Fe: serum iron.
Potential correlations between Hb concentration, 
serum levels of s-Fas, Epo, inflammatory cytokines and 
creatinine, the number of red blood cell units transfused 
and iron status were investigated in critically ill patients. 
Serum creatinine levels were positively correlated with 
serum IL-10 levels (r=0.44; p=0.004) and transferrin 
saturation (r=0.31; p=0.04). Serum Epo levels were 
positively correlated with serum IL-6 levels (r=0.31; 
p=0.04) and transferrin saturation (r=0.32; p=0.004). 
Serum s-Fas levels were positively correlated with serum 
IL-6 (r=0.63; p<0.001) and ferritin (r=0.46; p=0.002) 
levels, transferrin saturation (r=0.42; p=0.006), and the 
number of red blood cell units transfused (Figure 2). The 
number of red blood cell units transfused was positively 
correlated with transferrin saturation (r=0.32; p=0.04) 
and serum levels of IL-6 (r=0.31; p=0.04), ferritin 
(r=0.42; p=0.006) and iron (r=0.34; p=0.03), and 
negatively correlated with Hb concentrations (r=-0.36; 
p=0.02) (Figure 2, Table 2).
Serum s-Fas levels were the only predictors 
independently associated with red blood cell transfusion 
in critically ill patients in the first 28 days of follow-up 
when transferrin saturation and serum levels of ferritin, 
IL-6 and IL-10 were included in the model (binary 
logistic regression analysis; Table 3), and the only 
variable associated with the number of red blood cell 
units transfused (multiple linear regression; Table 4). 
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patients was analyzed in this follow-up study. Previously 
studied patient groups were evaluated to investigate the 
associations between Hb concentrations and serum levels 
of s-Fas, Epo, pro and anti-inflammatory cytokines. The 
impact of renal function on serum levels of these solutes 
was also investigated(13,14).
Critically ill patients potentially requiring red blood 
cell transfusions during the first 28 days in ICU were 
analyzed. Patients requiring red blood cell transfusions 
had higher serum levels of s-Fas, IL-6 and IL-10 and 
better iron status, but also higher mortality rates. 
In a binary logistic regression, serum s-Fas levels 
presented an independent association with red blood cell 
transfusion after adjusting for the levels of inflammatory 
cytokines and iron status in critically ill patients. We 
observed that serum level s-Fas was an independent 
predictor of red blood cell transfusion and that the 
addition of each thousand units in serum s-Fas levels 
increased the chance of needing red blood cell 
transfusion by eight fold. We also observed that serum 
s-Fas was an independent predictor of the number of 
packets of red blood cell transfused in multiple linear 
regression.
Anemia is a common condition in critically ill ICU 
patients(2,18) and the risks associated with allogeneic red 
blood cell transfusions have been well documented(19,20). 
In these patients, red blood cell transfusions are 
administered to increase oxygen delivery and tissue 
oxygenation, as red blood cells are the main transport 
mechanism for oxygen(21). In a large multicenter cohort 
study performed in the United States, 44% of critically 
ill patients received one or more red blood cell units 
while in ICU. In a European study, a 37% transfusion 
rate was reported in ICU patients(2,5). In the present 
study, the higher percentage (49%) of critically ill 
patients requiring red blood cell transfusions may have 
reflected the characteristics of the group studied (e.g. 
critically ill patients potentially requiring red blood cell 
transfusions during the first 28 days in ICU).
In this study, serum IL-6 levels were correlated 
with serum s-Fas and Epo levels in critically ill patients 
receiving red blood cell transfusions. Transfused patients 
in this group had more severe organ dysfunctions and 
higher serum levels of inflammatory cytokines, and 
therefore required red blood cell transfusions more 
often than the other patients studied. The association 
between serum s-Fas levels and the need for red blood 
cell transfusion due to anemia in critically ill patients 
has not been previously reported.
Higher serum s-Fas levels in patients with acute 
kidney injury and chronic kidney disease requiring renal 
replacement therapy suggest that serum s-Fas levels 
may reflect renal function status.
Some caveats must be considered in this study. First 
and foremost, unclear indications for transfusion of red 
blood cell may preclude inferences of a causal association 
between serum s-Fas levels and the need for red blood 
cell transfusion in critically ill patients. Most critically 
ill patients in this study suffered from AKI and were 
on renal replacement therapy, with expected impaired 
plasma clearance of some solutes. Also, the association 
between serum s-Fas levels and red blood cell transfusion 
could not be assessed in all groups due to the small 
number of subjects involved. Finally, the ability of serum 
s-Fas levels to predict the actual need for red blood cell 
transfusion in critically ill patients was based on a short 
(28 days) follow-up period. 
CONCLUSION
Serum s-Fas levels were associated with the need for 
red blood cell transfusions in critically ill patients in 
this study. critically ill patients requiring red blood cell 
transfusion had higher serum levels of s-Fas and IL-6, 
better iron status and higher mortality rates. S-Fas may 
play a role in the pathogenesis of anemia and may be 
used as a surrogate marker to predict the need for red 
blood cell transfusion in critically ill patients. Large 
randomized clinical cohort studies are warranted to 
further demonstrate the association between serum 
s-Fas levels and need for red blood cell transfusion in 
critically ill patients.
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